Brent Appelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brent Appelman has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Petrus Johannes Vlaar
Department of Intensive Care Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands
3 shared publications - Lonneke A. van Vught
Center for Experimental and Molecular Medicine, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications - Marleen A. Slim
Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2 shared publications - Matthijs C. Brouwer
Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications - Willem Joost Wiersinga
Center for Infection and Molecular Medicine, Amsterdam University Medical Center (Amsterdam UMC) , Amsterdam
2 shared publications - A. H. Ayesha Lavell
Department of Internal Medicine Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam The Netherlands
1 shared publication
Latest Publications
- Open Access
- 13 March 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (3) , e1222
Host Response Protein Biomarkers Indicative of Persistent Acute Kidney Injury in Critically Ill COVID-19 Patients
IMPORTANCE: Sepsis-related host-response anomalies contribute to acute kidney injury (AKI) duration. Data on the host-response specific to COVID-19-associated AKI (COVID-AKI) in critically ill patients is limited. OBJECTIVES: We postulated that persistent COVID-AKI (> 48 hr) differs in host response from transient (< 48 hr) or no COVID-AKI. DESIGN, SETTING, AND PARTICIPANTS: This prospective biomarker study observed patients with severe acute respiratory syndrome coronavirus 2 infection, without chronic kidney disease, in three ICUs from March 2020 to July 2020. AKI was assessed by hourly urine output and daily plasma creatinine. MAIN OUTCOMES AND MEASURES: Luminex and enzyme-linked immunosorbent assay were used to analyze 48 plasma protein biomarkers across six pathophysiological domains, which were tested with mixed-effects models. RESULTS: Of 177 included patients, 106 (59.9%) had AKI within the first 48 hours of admission, of whom 76 (71.7%) had persistent AKI and 30 (28.3%) transient AKI. Those with persistent AKI often had obesity, hypertension, and a higher Sequential Organ Failure Assessment score due to the renal component. Longitudinal analyses revealed that seven proteins were elevated in persistent AKI compared with no AKI. These were related to inflammation (triggering receptor expressed on myeloid cells 1, p < 0.001; tumor necrosis factor receptor 1, p < 0.001; procalcitonin, p = 0.001), complement activation (mannan-binding lectin serine protease-2, p = 0.001), kidney dysfunction (cystatin C, p < 0.001; neutrophil gelatinase-associated lipocalin, p < 0.001), and lung dysfunction (Clara cell secretory protein 16, p < 0.001). AKI (duration) was not associated with differences in the cytokine signaling, endothelial cell activation, or coagulation domains. CONCLUSIONS AND RELEVANCE: In contrast with sepsis-associated AKI, primarily inflammation-related biomarker levels correlated with COVID-AKI persistence. This study offers insights into COVID-AKI and may guide approaches to mitigate its persistence.
- 13 March 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (3) , e1222
Open AccessHost Response Protein Biomarkers Indicative of Persistent Acute Kidney Injury in Critically Ill COVID-19 Patients
IMPORTANCE: Sepsis-related host-response anomalies contribute to acute kidney injury (AKI) duration. Data on the host-response specific to COVID-19-associated AKI (COVID-AKI) in critically ill patients is limited. OBJECTIVES: We postulated that persistent COVID-AKI (> 48 hr) differs in host response from transient (< 48 hr) or no COVID-AKI. DESIGN, SETTING, AND PARTICIPANTS: This prospective biomarker study observed patients with severe acute respiratory syndrome coronavirus 2 infection, without chronic kidney disease, in three ICUs from March 2020 to July 2020. AKI was assessed by hourly urine output and daily plasma creatinine. MAIN OUTCOMES AND MEASURES: Luminex and enzyme-linked immunosorbent assay were used to analyze 48 plasma protein biomarkers across six pathophysiological domains, which were tested with mixed-effects models. RESULTS: Of 177 included patients, 106 (59.9%) had AKI within the first 48 hours of admission, of whom 76 (71.7%) had persistent AKI and 30 (28.3%) transient AKI. Those with persistent AKI often had obesity, hypertension, and a higher Sequential Organ Failure Assessment score due to the renal component. Longitudinal analyses revealed that seven proteins were elevated in persistent AKI compared with no AKI. These were related to inflammation (triggering receptor expressed on myeloid cells 1, p < 0.001; tumor necrosis factor receptor 1, p < 0.001; procalcitonin, p = 0.001), complement activation (mannan-binding lectin serine protease-2, p = 0.001), kidney dysfunction (cystatin C, p < 0.001; neutrophil gelatinase-associated lipocalin, p < 0.001), and lung dysfunction (Clara cell secretory protein 16, p < 0.001). AKI (duration) was not associated with differences in the cytokine signaling, endothelial cell activation, or coagulation domains. CONCLUSIONS AND RELEVANCE: In contrast with sepsis-associated AKI, primarily inflammation-related biomarker levels correlated with COVID-AKI persistence. This study offers insights into COVID-AKI and may guide approaches to mitigate its persistence.
- Open Access
- 19 July 2023
- Published by Elsevier in Thrombosis Research
- Vol. 229, 187-197
Thrombocytopenia is associated with a dysregulated host response in severe COVID-19
- 19 July 2023
- Published by Elsevier in Thrombosis Research
- Vol. 229, 187-197
Open AccessThrombocytopenia is associated with a dysregulated host response in severe COVID-19
- 28 October 2021
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (12) , 2677-2683
Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19
- 28 October 2021
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (12) , 2677-2683
Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19